Cargando…

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

CD19‐directed chimeric antigen receptor T‐cell therapy (CAR‐T) represents a significant advancement for patients with relapsed/refractory large B‐cell lymphoma (LBCL). Long‐term follow‐up confirms durable remissions in nearly half of the patients, a population that was previously estimated to have a...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Madiha, Savani, Bipin N, Hamadani, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725814/
https://www.ncbi.nlm.nih.gov/pubmed/34988550
http://dx.doi.org/10.1002/jha2.323

Ejemplares similares